{"organizations": [], "uuid": "851096a9a7a93cd760352f6eb1c04ef83a150a2c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biogen-reports-quarterly-revenues/brief-biogen-reports-quarterly-revenues-of-3-1-billion-idUSASC09WZH", "country": "US", "domain_rank": 408, "title": "BRIEF-Biogen Reports Quarterly Revenues Of $3.1 Billion", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.05, "site_type": "news", "published": "2018-04-24T19:07:00.000+03:00", "replies_count": 0, "uuid": "851096a9a7a93cd760352f6eb1c04ef83a150a2c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biogen-reports-quarterly-revenues/brief-biogen-reports-quarterly-revenues-of-3-1-billion-idUSASC09WZH", "ord_in_thread": 0, "title": "BRIEF-Biogen Reports Quarterly Revenues Of $3.1 Billion", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biogen inc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Biogen Inc:\n* BIOGEN REPORTS QUARTERLY REVENUES OF $3.1 BILLION * Q1 REVENUE $3.1 BILLION VERSUS I/B/E/S VIEW $3.16 BILLION\n* QTRLY NON-GAAP DILUTED EPS $6.05\n* QTRLY EARNINGS PER SHARE $5.54 * QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR\n* QTRLY PLEGRIDY REVENUE OF $100 MILLION VERSUS. $112 MILLION REPORTED LAST YEAR\n* QTRLY TYSABRI REVENUE OF $$462 MILLION VERSUS. $545 MILLION REPORTED LAST YEAR\n* QTRLY TECFIDERA REVENUE OF $987 MILLION VERSUS $958 MILLION REPORTED LAST YEAR\n* QTRLY AVONEX REVENUE OF $451 MILLION VERSUS $537 MILLION REPORTED LAST YEAR\n* Q1 EARNINGS PER SHARE VIEW $5.94 â€” THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-24T19:07:00.000+03:00", "crawled": "2018-04-25T15:01:37.007+03:00", "highlightTitle": ""}